Skip to main content

Errata - English

PDF CSV April 29, 2022 through April 29, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Sort descending Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
0.002 M EDETATE DISODIUM VS REAGENTS AND REFERENCE TABLES/Solutions USP43–NF38 6240 1-May-2020 NA NA Change
0.0744 g
to:
0.744 g
0.02 M EDETATE DISODIUM VS REAGENTS AND REFERENCE TABLES/Solutions USP43–NF38 6240 1-May-2020 NA NA Change
0.7444 g
to:
7.444 g
0.1 M ZINC SULFATE VS STANDARDIZATION USPNF Online Online 1-Dec-2022 NA NA In Standardization with visual end point: Change
M = mL edetate disodium × edetate disodium/mL ZnSO4
to:
M = mL edetate disodium × M edetate disodium/mL ZnSO4
AND
In Standardization with potentiometric end point… Read More
0.1 N POTASSIUM HYDROXIDE VS REAGENTS AND REFERENCE TABLES/Solutions USP42–NF37 6185 1-Dec-2019 NA NA Change
Standardization: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced.
to:
Standardization: Add 2 drops of phenolphthalein TS… Read More
0.1 N Potassium Permanganate VS STANDARDIZATION USPNF Online Online 1-Sep-2022 NA NA In Standardization with potentiometric endpoint: Change
N = g Na2C2O4/mL KMNnO4 solution × 0.06700
to:
N = g Na2C2O4/mL KMnO4 solution × 0.06700
2,5-DIHYDROXYBENZOIC ACID REAGENTS AND REFERENCE TABLES/Reagent Specifications USP42–NF37 6097 1-Dec-2019 NA NA Change
[303-07-1].
to:
[490-79-9].
25% TETRABUTYLAMMONIUM HYDROXIDE TS REAGENTS AND REFERENCE TABLES/Solutions Second Supplement to USP42–NF37 9336 1-Dec-2019 NA NA Change
Transfer about 34.82 g
to:
Transfer about 77.1 g
<1010> ANALYTICAL DATA—INTERPRETATION AND TREATMENT APPENDIX C: EXAMPLES OF OUTLIER TESTS FOR ANALYTICAL DATA/Hampel's Rule USP39–NF34 767 1-Oct-2016 USP41–NF36 First Supplement to USP40–NF35 Row 13 of Column 4 of Table 5. Test Results of Re-Applied Hampel's Rule: Change
0.14
to:
0.15
<1010> ANALYTICAL DATA—INTERPRETATION AND TREATMENT MEASUREMENT PRINCIPLES AND VARIATION USP42–NF37 7129 1-Mar-2019 NA NA See https://www.uspnf.com/sites/default/files/usp_pdf/EN/february_2019_errata_image1.pdf for correction
<1024> BOVINE SERUM APPENDIX 1 USP38–NF33 719 1-Oct-2015 USP40–NF35 First Supplement to USP39–NF34 Line 2 of bullet 1 of International Regulations and Guidance Documents in second paragraph: Change
http://www.emea.europa.eu/pdfs/human/bwp/026895en.pdf
to:
Read More
<1042> CELL BANKING PRACTICES FOR RECOMBINANT BIOLOGICS 5. CELL BANK CHARACTERIZATION USPNF Online Online 1-May-2023 NA NA In Table 4: Change
In vitro assayd,e + + +f
to:
In vitro assayd,e + −f +
<1046> CELL-BASED ADVANCED THERAPIES AND TISSUE-BASED PRODUCTS REGULATIONS AND STANDARDS USP43–NF38 7400 1-Nov-2020 NA NA In Table 5/Row 8 of Column 2: Change
221 CFR 1271
to:
21 CFR 1271
<1046> CELL-BASED ADVANCED THERAPIES AND TISSUE-BASED PRODUCTS ANALYTICAL METHODS USP43–NF38 7400 1-Nov-2020 NA NA In In-Process Controls/paragraph 2: Change
Refer to Risk Assessment for discussion on critical process parameters (CPP).
to:
Refer to Quality Systems for discussion on critical process parameters (CPP).
AND
In Final… Read More
<1047> GENE THERAPY PRODUCTS REGULATIONS AND STANDARDS USP38–NF33 883 1-Jun-2015 USP39–NF34 USP39–NF34 Line 8: Delete
and, in particular, www.fda.gov/cber/publications.htm
<1047> GENE THERAPY PRODUCTS APPENDIX USP38–NF33 883 1-Jun-2015 USP39–NF34 USP39–NF34 Line 8 of National and International Regulatory Documents: Delete
(http://www4.od.nih.gov/oba/guidelines.html)
<1050> VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN VI. Evaluation and Characterization of Viral Clearance Procedures USP35–NF30 553 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Row 10 (Reovirus 3) of Column 5 (Genome) of Table A-1: Change
DNA
to:
RNA
<1051> CLEANING GLASS APPARATUS CLEANING VALIDATION BEST PRACTICES USPNF 2021 ISSUE 1 Online 1-May-2021 NA NA Change
Quantitative Assessment of Cleaning Procedure
to:
Quantitative Assessment of Cleaning Process
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES USP36–NF31 619 1-Jun-2013 USP37–NF32 USP37–NF32 Change the section title
Method 6—Postcolumn DABS-CI Derivatization General Principle
to:
Method 6—Precolumn DABS-CI Derivatization General Principle
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS APPENDIX USP36–NF31 619 1-Jun-2013 USP37–NF32 USP37–NF32 Change the section title
Method 6—Postcolumn DABS-CI Derivatization
to:
Method 6—Precolumn DABS-CI Derivatization
<1056> BIOTECHNOLOGY-DERIVED ARTICLES -- POLYACRYLAMIDE GEL ELECTROPHORESIS INTRODUCTION Harmonization (Official December 01, 2015) Online 1-Aug-2015 USP40–NF35 First Supplement to USP39–NF34 A paragraph before the Introduction was deleted:
This chapter provides guidance and procedures used for characterization of biotechnology-derived articles by polyacrylamide gel electrophoresis. Portions of the chapter that are not harmonized with the other two pharmacopeias are marked by… Read More
<1058> ANALYTICAL INSTRUMENT QUALIFICATION ANALYTICAL INSTRUMENT QUALIFICATION PROCESS/Qualification Phases First Supplement to USP40–NF35 8083 1-Feb-2017 USP41–NF36 Second Supplement to USP40–NF35 Line 2 of paragraph 1 of Operational Qualification: Change
OQ demonstrates fitness for the selected use, and should reflect the contents of the DQ document.
to:
OQ demonstrates fitness for the selected use, and should reflect URS.
AND
Line 2 of paragraph 3 of Operational… Read More
<1079> GOOD STORAGE AND DISTRIBUTION PRACTICES FOR DRUG PRODUCTS QUALITY MANAGEMENT SYSTEM/Storage Management System/Receiving and Transferring Drug Products USP36–NF31 693 1-Apr-2013 USP37–NF32 USP37–NF32 Line 1 of footnote 1: Change
JP Edmond,
to:
JP Emond,
<1079> RISKS AND MITIGATION STRATEGIES FOR THE STORAGE AND TRANSPORTATION OF FINISHED DRUG PRODUCTS 4. RISK MITIGATION CATEGORIES AS QMS ELEMENTS Second Supplement to USP43–NF38 Online 1-Feb-2021 NA NA In 4.1 Documentation and Procedures/4.1.3 Labels: Change
The use of symbols that are recognized by international organizations is strongly recommended.
to:
The use of symbols that are recognized by international organizations is strongly… Read More
<1085> GUIDELINES ON THE ENDOTOXINS TEST METHOD SUITABILITY USP43–NF38 7665 1-Dec-2020 NA NA In Row 2 of Column 3 of Table 3: Change
hydrochloride
to:
hydrochloric acid
AND
In paragraph 2 of Method Suitability Testing/Common Test Interferences: Change
hydrochloride
to:
hydrochloric acid
<1092> THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION 1. PRELIMINARY ASSESSMENT Second Supplement to USP43–NF38 Online 1-Dec-2020 NA NA In paragraph 4 of 1.4 Choosing an apparatus: Change
peak vessels
to:
apex vessels
<1092> THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION 6. ACCEPTANCE CRITERIA Second Supplement to USP43–NF38 Online 1-Dec-2020 NA NA In Row 1 of Table 5 and Table 6: Align Times with Acceptance Criteria
<1092> THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION 2. METHOD DEVELOPMENT Second Supplement to USP43–NF38 Online 1-Dec-2020 NA NA In paragraph 2 of 2.4 Study Design/2.4.1 Time Points: Change
Assessment of Drug Product Performance—Bioavailability, Bioequivalence, and Dissolution 〈1090〉.
to:
Assessment of Solid Oral Drug Product Performance and… Read More
<1103> IMMUNOLOGICAL TEST METHODS—ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) PROCEDURES/Solid Phase USP40–NF35 1344 1-Feb-2018 USP42–NF37 Second Supplement to USP41–NF36 Line 7 of Coating the Solid Phase—Immobilization of Capture Reagent: Change
1–10 µg/well
to:
1–10 µg/mL
<111> DESIGN AND ANALYSIS OF BIOLOGICAL ASSAYS COMBINATION OF INDEPENDENT ASSAYS/Method 2 USP43–NF38 6543 1-Aug-2020 NA NA In the second bullet in Alternate weights for inter-assay component of variation: Delete the duplicate equation
<1125> NUCLEIC ACID-BASED TECHNIQUES -- GENERAL APPENDICES USP43–NF38 7865 1-May-2020 NA NA In Appendix 2: Delete the Row for
dNTP dinucleotide triphosphate
<1125> NUCLEIC ACID-BASED TECHNIQUES—GENERAL APPENDICES/Appendix 1: Regulations and Standards USP40–NF35 1471 1-Jun-2017 USP41–NF36 USP41–NF36 Line 1 of bullet 1: Change
"Review Criteria for Nucleic Acid Amplification-Based In Vitro Diagnostic Devices for Direct Detection of Infectious Microorganisms" (1993)
to:
"Nucleic Acid Based In Vitro Diagnostic Devices for Detection of Microbial Pathogens" (2005)
<1125> NUCLEIC ACID-BASED TECHNIQUES—GENERAL APPENDICES/Appendix 1 USP43–NF38 7865 1-Aug-2020 NA NA In footnote 1: Change
http://ts.nist.gov/measurementservices/referencematerials/index.cfm.
to:
https://www.nist.gov/srm.
<1132> RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS 4. HCP IMMUNOASSAY METHOD VALIDATION/4.3 Sample Linearity/Table 4 Second Supplement to USP38–NF33 7647 1-Apr-2016 USP40–NF35 USP40–NF35 Product column: Change
10.00 (neat), 5.00, 2.50, 1.25, 0.63, 0.31, 0.16
to:
10.00 (neat), 5.00, 2.50, 1.25, 0.625, 0.3125, 0.15625
AND
Sample 1/HCP ratio column: Change
4.9, 5.7, 4.8, 5.9, 5.0, 5.1, <6
to:
4.90, 5.70, 4.80, 5.92, 4.96, 5.12, <6
AND… Read More
<1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE 10. ALLIGATION ALTERNATE AND ALGEBRA METHODS FOR COMBINING MULTIPLE STRENGTHS OF THE SAME ACTIVE PHARMACEUTICAL INGREDIENT USP42–NF37 7831 1-May-2019 NA NA In 10.2 Algebra Method/10.2.1 Calculating by using the algebra method/Examples—Algebra method:
In example 2, in equations 1, 2, 3, and 4 in all instances: Change
Cs
to:
Qs
AND
In example… Read More
<1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE 19. MEAN KINETIC TEMPERATURE USP42–NF37 7831 1-Sep-2019 NA NA In 19.4 Example Calculations of MKT for CRT Storage Evaluation/Example 3—Calculation of Annual MKTStep 3: Change
3.354
to:
3.340
AND
In Step 4: Change
2.795
to:
2.783
AND
In Step 5:… Read More
<1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE 19. MEAN KINETIC TEMPERATURE/19.2 MKT Equation USP42–NF37 7831 1-May-2019 NA NA In the variable definition list: Change
Tn = value for the total number of storage temperatures recorded during the observation period temperature recorded during the nth time period, e.g., nth week
to:
Tn Read More
<1197> GOOD DISTRIBUTION PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS SECTION 2: QUALITY, ORGANIZATION, AND DOCUMENTATION/2.8 Contract Activities USP38–NF33 1396 1-Jun-2015 USP39–NF34 USP39–NF34 Footnote 2: Change
http://whqlibdoc.who.int/trs/WHO_TRS_917_annex2.pdf (Accessed June 30, 2011)
to:
Read More
<1197> GOOD DISTRIBUTION PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS SECTION 4: RETURNED GOODS, DISPATCH, TRANSPORT, IMPORTATION, ADULTERATION, AND TRACEABILITY/4.7 Importation USP38–NF33 1396 1-Jun-2015 USP39–NF34 USP39–NF34 Footnote 11: Delete
http://www.fda.gov/ForIndustry/ImportProgram/AdmissibilityDeterminationsforShipmentsofForeign-originOASIS/ucm077691.htm (Accessed June 6,… Read More
<1207> STERILE PRODUCT PACKAGING−INTEGRITY EVALUATION 5. PRODUCT–PACKAGE QUALITY REQUIREMENTS AND THE MAXIMUM ALLOWABLE LEAKAGE LIMIT/5.1 Sterility and Product Formulation Content must be Preserved; Gas Headspace Content Preservation is not Required First Supplement to USP39–NF34 7764 1-Dec-2016 USP41–NF36 Second Supplement to USP40–NF35 Line 3 of paragraph 5: Change
ultra-cold storage (<80°)
to:
ultra-cold storage (≤−80°)
<1210> STATISTICAL TOOLS FOR PROCEDURE VALIDATION 3. ACCURACY AND PRECISION/3.1 Methods for Estimating Accuracy and Precision USP41–NF36 7622 1-Mar-2018 USP42–NF37 Second Supplement to USP41–NF36 Paragraph 4: Change
For example, with ɑ = 0.05 and n = 9, t0.95:8 = 1.860 provides a 100(1− 2 × 1.05)%
to:
For example, with ɑ = 0.05 and n = 9, t0.95:8 = 1.860 provides a 100(1 − 2 × 0.05)%
<1210> STATISTICAL TOOLS FOR PROCEDURE VALIDATION 3. ACCURACY AND PRECISION USP41–NF36 7622 1-May-2018 USP42–NF37 Second Supplement to USP41–NF36 Line 4 of paragraph 3 of 3.2 Combined Validation of Accuracy and Precision: Change
validate evaluate
to:
validate
AND
Variable definition in paragraph 6 of 3.2 Combined Validation of Accuracy and Precision:… Read More
<121> INSULIN ASSAYS ASSAY/Rabbit Blood Sugar Method—Quantitative Revision Bulletin (Official May 01, 2019) Online 1-Jan-2020 NA NA In Standard stock solution: Change
of USP Insulin RS of the appropriate species
to:
of the USP Insulin Reference Standard of the appropriate species
AND
In Sample stock solution: Change
of USP Insulin RS of the appropriate species.… Read More
<121> INSULIN ASSAYS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP41–NF36 6054 1-Oct-2018 USP43–NF38 Second Supplement to USP41–NF36 This erratum applies to the new USP-NF ONLINE platform only.
Delete
USP Insulin RS
<1222> TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE INTRODUCTION USP42–NF37 8021 1-Nov-2019 NA NA In paragraphs 4 and 5: Change
a probability of a PNSU
to:
a PNSU
<1227> VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES VALIDATION OF NEUTRALIZATION METHODS—RECOVERY COMPARISONS Second Supplement to USP42–NF37 9616 1-Dec-2019 NA NA In paragraph 1 in Recovery on Agar Medium: Change
If it is necessary to solubilize the test stample,
to:
If it is necessary to solubilize the test sample,
<1228.1> DRY HEAT DEPYROGENATION INTRODUCTION USPNF Online Online 1-Mar-2024 NA NA Change
parental manufacturing
to:
parenteral manufacturing
<1228.4> DEPYROGENATION BY RINSING ROUTINE PROCESS CONTROL USP42–NF37 8067 1-Nov-2019 NA NA In the first paragraph: Change
WFI
to:
Water for Injection
<1229.2> STEAM STERILIZATION OF AQUEOUS LIQUIDS BIOBURDEN/BIOLOGICAL INDICATOR METHOD/Routine Process Control USP42–NF37 8082 1-Nov-2019 NA NA In the first paragraph: Change
calibrartion
to:
calibration
<123> GLUCAGON BIOIDENTITY TESTS PROCEDURE/B. In Vitro Cell-Based Bioidentity Test First Supplement to USP41–NF36 8627 1-Aug-2018 USP43–NF38 Second Supplement to USP41–NF36 Line 1 of Medium B: Change
Kreb's salt solution containing 0.3% (v/v) human serum albumen
to:
Krebs' salt solution containing 0.3% (v/v) human serum albumin
AND
Line 1 of Medium C: change
Kreb's salt solution containing 0.3% (v/v)… Read More
<123> GLUCAGON BIOIDENTITY TESTS PROCEDURE/B. In Vitro Cell-Based Bioidentity Test USP42–NF37 6478 1-Aug-2019 NA NA In Standard stock solution: Change
0.4 µg/mL
to:
4 µg/mL